PMC:7283670 / 79901-80316 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T434","span":{"begin":237,"end":240},"obj":"Disease"},{"id":"T435","span":{"begin":335,"end":338},"obj":"Disease"}],"attributes":[{"id":"A434","pred":"mondo_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A435","pred":"mondo_id","subj":"T435","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"}],"text":"24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T669","span":{"begin":151,"end":153},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T670","span":{"begin":249,"end":251},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T671","span":{"begin":327,"end":331},"obj":"http://purl.obolibrary.org/obo/CLO_0053809"},{"id":"T672","span":{"begin":347,"end":349},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T318","span":{"begin":193,"end":198},"obj":"Chemical"},{"id":"T319","span":{"begin":291,"end":296},"obj":"Chemical"},{"id":"T320","span":{"begin":387,"end":392},"obj":"Chemical"}],"attributes":[{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one "}

{"project":"LitCovid-sentences","denotations":[{"id":"T703","span":{"begin":19,"end":264},"obj":"Sentence"},{"id":"T704","span":{"begin":265,"end":296},"obj":"Sentence"},{"id":"T705","span":{"begin":297,"end":362},"obj":"Sentence"},{"id":"T706","span":{"begin":363,"end":392},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one "}

{"project":"LitCovid-PubTator","denotations":[{"id":"1939","span":{"begin":84,"end":101},"obj":"Species"},{"id":"1940","span":{"begin":111,"end":128},"obj":"Species"},{"id":"1941","span":{"begin":241,"end":245},"obj":"Species"},{"id":"1942","span":{"begin":339,"end":343},"obj":"Species"}],"attributes":[{"id":"A1939","pred":"tao:has_database_id","subj":"1939","obj":"Tax:2697049"},{"id":"A1940","pred":"tao:has_database_id","subj":"1940","obj":"Tax:28285"},{"id":"A1941","pred":"tao:has_database_id","subj":"1941","obj":"Tax:2697049"},{"id":"A1942","pred":"tao:has_database_id","subj":"1942","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one "}